Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury.
OBJECTIVE This study examines whether continuation therapy with citalopram can prevent a relapse following remission of major depression due to traumatic brain injury . METHOD After 65 subjects with DSM-IV-diagnosed major depression following traumatic brain injury were treated with open-label citalopram ( 20 mg to 50 mg/d ) , 25 subjects ( 38.5 % ) met criteria for remission . Of those , 21 ( 84.0 % ) were r and omly assigned to either same-dose citalopram or placebo and followed monthly over 40 weeks . Remission was defined as a Hamilton Depression Rating Scale ( HDRS ) score of ≤ 7 or a Clinical Global Impressions-Improvement rating of " much improved " or better . The main outcome variable was the presence of relapse , as defined by meeting criteria for major depressive episode according to the DSM-IV and an HDRS score ≥ 16 . Data were collected from February 16 , 2005 , to May 5 , 2008 . RESULTS Ten subjects were r and omly assigned to citalopram and 11 to placebo . There were 3 dropouts , including 1 for adverse drug effects ( diarrhea ) . Relapse occurred in 11 subjects ( 52.4 % ) , with a mean ± SD time to relapse of 23.52 ± 16.6 weeks . The groups did not differ in relapse rates ( drug : 50.0 % [ 5/10 ] vs placebo : 54.5 % [ 6/11 ] , Fisher exact test , P = .835 ) or time to relapse ( log rank test χ² = 0.148 , P = .700 ) . CONCLUSIONS The present study suggests important limitations of continuation pharmacotherapy in the prevention of relapse of major depression following traumatic brain injury . TRIAL REGISTRATION clinical trials.gov Identifier : NCT00162916
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .